Literature DB >> 23658294

G34, another connection between MYCN and a pediatric tumor.

Miller Huang1, William A Weiss.   

Abstract

Recurrent mutations in H3F3A at K27 and G34 are frequent in pediatric glioblastoma, but it is unclear how these mutations promote tumorigenesis. In this issue of Cancer Discovery, Bjerke and colleagues identify mutations at G34 in H3F3A that result in elevated expression of MYCN as a potential mechanism in gliomagenesis.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23658294      PMCID： PMC4120990          DOI： 10.1158/2159-8290.CD-13-0126

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  8 in total

1.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.

Authors:  Jeremy Schwartzentruber; Andrey Korshunov; Xiao-Yang Liu; David T W Jones; Elke Pfaff; Karine Jacob; Dominik Sturm; Adam M Fontebasso; Dong-Anh Khuong Quang; Martje Tönjes; Volker Hovestadt; Steffen Albrecht; Marcel Kool; Andre Nantel; Carolin Konermann; Anders Lindroth; Natalie Jäger; Tobias Rausch; Marina Ryzhova; Jan O Korbel; Thomas Hielscher; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Martin Ebinger; Martin U Schuhmann; Wolfram Scheurlen; Arnulf Pekrun; Michael C Frühwald; Wolfgang Roggendorf; Christoph Kramm; Matthias Dürken; Jeffrey Atkinson; Pierre Lepage; Alexandre Montpetit; Magdalena Zakrzewska; Krzystof Zakrzewski; Pawel P Liberski; Zhifeng Dong; Peter Siegel; Andreas E Kulozik; Marc Zapatka; Abhijit Guha; David Malkin; Jörg Felsberg; Guido Reifenberger; Andreas von Deimling; Koichi Ichimura; V Peter Collins; Hendrik Witt; Till Milde; Olaf Witt; Cindy Zhang; Pedro Castelo-Branco; Peter Lichter; Damien Faury; Uri Tabori; Christoph Plass; Jacek Majewski; Stefan M Pfister; Nada Jabado
Journal:  Nature       Date:  2012-01-29       Impact factor: 49.962

Review 2.  Histone regulation in the CNS: basic principles of epigenetic plasticity.

Authors:  Ian Maze; Kyung-Min Noh; C David Allis
Journal:  Neuropsychopharmacology       Date:  2012-07-25       Impact factor: 7.853

3.  Targeting MYCN in neuroblastoma by BET bromodomain inhibition.

Authors:  Alexandre Puissant; Stacey M Frumm; Gabriela Alexe; Christopher F Bassil; Jun Qi; Yvan H Chanthery; Erin A Nekritz; Rhamy Zeid; William Clay Gustafson; Patricia Greninger; Matthew J Garnett; Ultan McDermott; Cyril H Benes; Andrew L Kung; William A Weiss; James E Bradner; Kimberly Stegmaier
Journal:  Cancer Discov       Date:  2013-02-21       Impact factor: 39.397

4.  Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.

Authors:  Fredrik J Swartling; Vasil Savov; Anders I Persson; Justin Chen; Christopher S Hackett; Paul A Northcott; Matthew R Grimmer; Jasmine Lau; Louis Chesler; Arie Perry; Joanna J Phillips; Michael D Taylor; William A Weiss
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

5.  Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.

Authors:  Sriram Venneti; Mihir T Garimella; Lisa M Sullivan; Daniel Martinez; Jason T Huse; Adriana Heguy; Mariarita Santi; Craig B Thompson; Alexander R Judkins
Journal:  Brain Pathol       Date:  2013-03-06       Impact factor: 6.508

6.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Authors:  Dominik Sturm; Hendrik Witt; Volker Hovestadt; Dong-Anh Khuong-Quang; David T W Jones; Carolin Konermann; Elke Pfaff; Martje Tönjes; Martin Sill; Sebastian Bender; Marcel Kool; Marc Zapatka; Natalia Becker; Manuela Zucknick; Thomas Hielscher; Xiao-Yang Liu; Adam M Fontebasso; Marina Ryzhova; Steffen Albrecht; Karine Jacob; Marietta Wolter; Martin Ebinger; Martin U Schuhmann; Timothy van Meter; Michael C Frühwald; Holger Hauch; Arnulf Pekrun; Bernhard Radlwimmer; Tim Niehues; Gregor von Komorowski; Matthias Dürken; Andreas E Kulozik; Jenny Madden; Andrew Donson; Nicholas K Foreman; Rachid Drissi; Maryam Fouladi; Wolfram Scheurlen; Andreas von Deimling; Camelia Monoranu; Wolfgang Roggendorf; Christel Herold-Mende; Andreas Unterberg; Christof M Kramm; Jörg Felsberg; Christian Hartmann; Benedikt Wiestler; Wolfgang Wick; Till Milde; Olaf Witt; Anders M Lindroth; Jeremy Schwartzentruber; Damien Faury; Adam Fleming; Magdalena Zakrzewska; Pawel P Liberski; Krzysztof Zakrzewski; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Sorana Morrissy; Florence Cavalli; Michael D Taylor; Peter van Sluis; Jan Koster; Rogier Versteeg; Richard Volckmann; Tom Mikkelsen; Kenneth Aldape; Guido Reifenberger; V Peter Collins; Jacek Majewski; Andrey Korshunov; Peter Lichter; Christoph Plass; Nada Jabado; Stefan M Pfister
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

7.  Development and implementation of a high-throughput AlphaLISA assay for identifying inhibitors of EZH2 methyltransferase.

Authors:  Jeffrey R Simard; Matthew Plant; Renee Emkey; Violeta Yu
Journal:  Assay Drug Dev Technol       Date:  2013-02-14       Impact factor: 1.738

8.  Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.

Authors:  Gang Wu; Alberto Broniscer; Troy A McEachron; Charles Lu; Barbara S Paugh; Jared Becksfort; Chunxu Qu; Li Ding; Robert Huether; Matthew Parker; Junyuan Zhang; Amar Gajjar; Michael A Dyer; Charles G Mullighan; Richard J Gilbertson; Elaine R Mardis; Richard K Wilson; James R Downing; David W Ellison; Jinghui Zhang; Suzanne J Baker
Journal:  Nat Genet       Date:  2012-01-29       Impact factor: 38.330
  8 in total
  5 in total

1.  Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.

Authors:  Franz X Schaub; Varsha Dhankani; Ashton C Berger; Mihir Trivedi; Anne B Richardson; Reid Shaw; Wei Zhao; Xiaoyang Zhang; Andrea Ventura; Yuexin Liu; Donald E Ayer; Peter J Hurlin; Andrew D Cherniack; Robert N Eisenman; Brady Bernard; Carla Grandori
Journal:  Cell Syst       Date:  2018-03-28       Impact factor: 10.304

2.  Molecular Diagnostic and Prognostic Subtyping of Gliomas in Tunisian Population.

Authors:  Saoussen Trabelsi; Imen Chabchoub; Iadh Ksira; Nadhir Karmeni; Nadia Mama; Samia Kanoun; Anna Burford; Alexa Jury; Alan Mackay; Sergey Popov; Noureddine Bouaouina; Slim Ben Ahmed; Moncef Mokni; Kalthoum Tlili; Hedi Krifa; Mohamed Tahar Yacoubi; Chris Jones; Ali Saad; Dorra H'mida Ben Brahim
Journal:  Mol Neurobiol       Date:  2016-03-09       Impact factor: 5.590

3.  A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers.

Authors:  Hussain Elhasasna; Raymond Khan; Kalpana K Bhanumathy; Frederick S Vizeacoumar; Prachi Walke; Maricris Bautista; Dinesh K Dahiya; Vincent Maranda; Hardikkumar Patel; Amrutha Balagopal; Nezeka Alli; Anand Krishnan; Andrew Freywald; Franco J Vizeacoumar
Journal:  Cells       Date:  2022-07-20       Impact factor: 7.666

4.  Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults.

Authors:  Thiébaud Picart; Marc Barritault; Delphine Poncet; Lise-Prune Berner; Cristina Izquierdo; Emeline Tabouret; Dominique Figarella-Branger; Ahmed Idbaïh; Franck Bielle; Véronique Bourg; Fanny Burel Vandenbos; Elizabeth Cohen-Jonathan Moyal; Emmanelle Uro-Coste; Jacques Guyotat; Jérôme Honnorat; Mathieu Gabut; David Meyronet; François Ducray
Journal:  Neurooncol Adv       Date:  2021-04-19

5.  Driver mutations of cancer epigenomes.

Authors:  David M Roy; Logan A Walsh; Timothy A Chan
Journal:  Protein Cell       Date:  2014-03-14       Impact factor: 14.870
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.